Why did ncna surge?


Aime
The stock of NuCana (NASDAQ:NCNA) experienced a significant surge from September 16 to September 231, which can be attributed to the following factors:
- Encouraging Clinical Trial Data: NuCana presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for metastatic melanoma patients refractory to or had relapsed on prior PD-1 inhibitor therapy. The study showed that out of 12 patients, 9 (75%) achieved disease control, including 2 patients who achieved Partial Responses. Seven of the 12 patients had a progression-free survival time of over five months, which is significantly higher than the median progression-free survival of 2-3 months with the current standard of care. This encouraging efficacy signal, along with a favorable safety profile, contributed to the positive sentiment towards NuCana's stock23.
- Issuance of a New Patent: NuCana announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is expected to serve as a key component of the intellectual property protection for NUC-7738, which currently consists of over 80 issued patents worldwide. The grant of this patent further strengthens the intellectual property protection of NUC-7738 and its ability to make previously resistant tumors sensitive to rechallenge with PD-1 inhibitors by targeting multiple aspects of the tumor microenvironment4.
In summary, the surge in NuCana's stock price can be attributed to the promising clinical trial data and the issuance of a new patent, which have bolstered investor confidence in the company's potential to improve treatment outcomes for cancer patients.
Source:
1.
NCNA Percentage Change For Recent 2 Weeks Day By Day
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki